NASDAQ: ELDN
Eledon Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for ELDN

Based on 1 analyst offering 12 month price targets for Eledon Pharmaceuticals Inc

Min Forecast
$16.00+389.3%
Avg Forecast
$16.00+389.3%
Max Forecast
$16.00+389.3%

Should I buy or sell ELDN stock?

Based on 1 analyst offering ratings for Eledon Pharmaceuticals Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ELDN's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ELDN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ELDN stock forecasts and price targets.

ELDN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-11-20

1 of 1

Forecast return on equity

Is ELDN forecast to generate an efficient return?

Company
-68.93%
Industry
146.26%
Market
80.85%
ELDN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ELDN forecast to generate an efficient return on assets?

Company
-45.91%
Industry
36.38%
ELDN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ELDN earnings per share forecast

What is ELDN's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.10
Avg 2 year Forecast
-$0.98
Avg 3 year Forecast
-$1.38

ELDN revenue forecast

What is ELDN's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$17.4M
Avg 2 year Forecast
$109.0M
Avg 3 year Forecast
$193.0M

ELDN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELDN$3.27$16.00+389.30%Buy
MDWD$18.16$32.00+76.21%Buy
FULC$3.65$4.00+9.59%Hold
NGNE$13.03$54.00+314.43%Buy
VYGR$3.59$13.95+289.01%Strong Buy

Eledon Pharmaceuticals Stock Forecast FAQ

Is Eledon Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ELDN) stock is to Buy ELDN stock.

Out of 1 analyst, 0 (0%) are recommending ELDN as a Strong Buy, 1 (100%) are recommending ELDN as a Buy, 0 (0%) are recommending ELDN as a Hold, 0 (0%) are recommending ELDN as a Sell, and 0 (0%) are recommending ELDN as a Strong Sell.

If you're new to stock investing, here's how to buy Eledon Pharmaceuticals stock.

What is ELDN's earnings growth forecast for 2025-2027?

(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Eledon Pharmaceuticals's earnings in 2025 is -$36,184,000.On average, 4 Wall Street analysts forecast ELDN's earnings for 2025 to be -$65,720,248, with the lowest ELDN earnings forecast at -$73,654,583, and the highest ELDN earnings forecast at -$58,684,140. On average, 2 Wall Street analysts forecast ELDN's earnings for 2026 to be -$58,384,731, with the lowest ELDN earnings forecast at -$66,468,770, and the highest ELDN earnings forecast at -$50,300,691.

In 2027, ELDN is forecast to generate -$82,636,850 in earnings, with the lowest earnings forecast at -$82,636,850 and the highest earnings forecast at -$82,636,850.

What is ELDN's revenue growth forecast for 2028-2030?

(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Eledon Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ELDN's revenue for 2028 to be $1,041,942,885, with the lowest ELDN revenue forecast at $1,041,942,885, and the highest ELDN revenue forecast at $1,041,942,885. On average, 1 Wall Street analysts forecast ELDN's revenue for 2029 to be $6,527,113,475, with the lowest ELDN revenue forecast at $6,527,113,475, and the highest ELDN revenue forecast at $6,527,113,475.

In 2030, ELDN is forecast to generate $11,557,182,575 in revenue, with the lowest revenue forecast at $11,557,182,575 and the highest revenue forecast at $11,557,182,575.

What is ELDN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ELDN) forecast ROA is -45.91%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is ELDN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ELDN price target, the average ELDN price target is $16.00, with the highest ELDN stock price forecast at $16.00 and the lowest ELDN stock price forecast at $16.00.

The Wall Street analyst predicted that Eledon Pharmaceuticals's share price could reach $16.00 by Nov 20, 2025. The average Eledon Pharmaceuticals stock price prediction forecasts a potential upside of 389.3% from the current ELDN share price of $3.27.

What is ELDN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ELDN) Eledon Pharmaceuticals's current Earnings Per Share (EPS) is -$0.75. On average, analysts forecast that ELDN's EPS will be -$1.10 for 2025, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$0.98. On average, analysts forecast that ELDN's EPS will be -$0.98 for 2026, with the lowest EPS forecast at -$1.11, and the highest EPS forecast at -$0.84. In 2027, ELDN's EPS is forecast to hit -$1.38 (min: -$1.38, max: -$1.38).

What is ELDN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ELDN) forecast ROE is -68.93%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.